As long as the patient is not susceptible to diabetic ketoacidosis, the recently introduced sodium-glucose co-transporter-2 (SGLT2) inhibitors may be used in patients both with insulin resistance and those with altered insulin secretion [8,19]. This evidence concerns the gene SLC5A2 and Insulin resistance.